{
    "pmcid": "9082315",
    "qa_pairs": {
        "What challenge does the omicron variant pose to existing vaccines and therapeutics?": [
            "Its extensive RBD mutations",
            "Its increased replication rate",
            "Its ability to evade T-cell responses",
            "Its enhanced transmission via aerosols"
        ],
        "What is the primary target for neutralizing antibodies on the SARS-CoV-2 spike protein?": [
            "The receptor-binding motif (RBM) within the receptor-binding domain (RBD)",
            "The S2 subunit of the spike protein",
            "The N-terminal domain of the spike protein",
            "The membrane fusion peptide of the spike protein"
        ],
        "What was the source of the nanobodies used in the study targeting the SARS-CoV-2 RBD?": [
            "Dromedary camels immunized with the SARS-CoV-2 RBD",
            "Llamas immunized with the SARS-CoV-2 S protein",
            "Mice immunized with the SARS-CoV-2 spike protein",
            "Rabbits immunized with the SARS-CoV-2 nucleocapsid protein"
        ],
        "Which group of nanobodies showed potential for cross-variant neutralization by binding to conserved regions outside the RBM?": [
            "Group B nanobodies",
            "Group A nanobodies",
            "Group C nanobodies",
            "Group D nanobodies"
        ],
        "Which variants of SARS-CoV-2 have mutations such as N501Y, E484K, and L452R?": [
            "Alpha, beta, gamma, delta, and omicron",
            "Alpha, beta, gamma, and epsilon",
            "Delta, epsilon, lambda, and mu",
            "Beta, gamma, lambda, and theta"
        ]
    }
}